Lehmann W, Böhmer F D, Karsten U, Graetz H, Koberling A, Kunde D, Langen P
Eur J Cancer Clin Oncol. 1987 Jan;23(1):69-74. doi: 10.1016/0277-5379(87)90421-4.
The mutant substrain HD33 of the Ehrlich-Lettré ascites mammary carcinoma (EAC) was found to be altered in its ability to respond to and to produce natural growth inhibitors. Cells of this substrain did not respond to (1) a highly purified growth inhibitor from bovine mammary gland, inhibiting the proliferation of two strains of the original EAC already at concentrations of 0.5-2.0 ng/ml, (2) inhibitory activities found in the ascites fluid of these sensitive strains and partially purified. However, from the ascites fluid of the mutant substrain an inhibitory activity was partially purified, which was inhibitory towards this substrain. It also inhibited the cells from an original strain, although less effectively. This new inhibitory activity is similar in its properties to that of the others investigated in that its mol. wt is between 10,000 and 50,000 D, it is heat labile and its activity can be overcome by insulin, epidermal growth factor and 2'-deoxycytidine, the dose-response curve levels off at 35-45% inhibition. The results demonstrate that the regulation of cell proliferation by endogenous (autocrine) inhibitors can be altered by mutagen treatment.
艾氏-莱特腹水型乳腺癌（EAC）的突变亚系HD33被发现对天然生长抑制剂的反应能力和产生能力发生了改变。该亚系细胞对以下物质无反应：（1）一种来自牛乳腺的高度纯化的生长抑制剂，其在浓度为0.5 - 2.0 ng/ml时就能抑制原始EAC的两个菌株的增殖；（2）在这些敏感菌株的腹水中发现并部分纯化的抑制活性物质。然而，从突变亚系的腹水中部分纯化出了一种抑制活性物质，它对该亚系具有抑制作用。它对原始菌株的细胞也有抑制作用，尽管效果稍差。这种新的抑制活性物质的性质与其他研究过的抑制活性物质相似，其分子量在10,000至50,000 D之间，对热不稳定，其活性可被胰岛素、表皮生长因子和2'-脱氧胞苷克服，剂量-反应曲线在35 - 45%抑制时趋于平稳。结果表明，诱变处理可改变内源性（自分泌）抑制剂对细胞增殖的调节作用。
